Splash Beverage Group, INC 8-K filings

Endovia Health Sciences has amended its equity line of credit facility with C/M Capital Master Fund, LP, increasing the beneficial ownership limitation.

Endovia Health Sciences disclosed the sale of 526,582 shares of common stock for gross proceeds of $81,830.84 under an existing agreement.

Endovia Health Sciences announced its investigational drug CannEpil has been determined by the FDA to qualify as a minor use for canine bone cancer pain, paving the way for conditional approval.

Endovia Health Sciences, Inc. has issued a secured convertible promissory note to C/M Capital Master Fund, LP, for $510,000, with provisions for conversion into common stock and specific repayment terms.

Endovia Health Sciences announced the closure of an initial $500,000 financing tranche from C/M Capital to advance its CannEpil development program, coinciding with increased federal support for botanical drug pathways.

Endovia Health Sciences announced progress on its CannEpil FDA submission and welcomed a potential shift in federal cannabinoid policy towards Schedule III.

Endovia Health Sciences, Inc. disclosed the sale of 510,951 shares of common stock for gross proceeds of $107,610.62 under an existing agreement.

Endovia Health Sciences, Inc. has entered into employment agreements with Brady Cobb as Interim CEO and Michael Bondurant as Interim COO, detailing compensation and performance-based bonuses tied to market capitalization.

Endovia Health Sciences announced it has achieved its first FDA regulatory milestone for its CannEpil veterinary development program, establishing an Investigational New Animal Drug (INAD) file.

Splash Beverage Group, Inc. announced its corporate name change to Endovia Health Sciences, Inc., with a new ticker symbol EDVA, effective August 24, 2026, signaling a strategic pivot to cannabinoid-based health sciences.

Splash Beverage Group announced second quarter 2026 results, detailing a 64% reduction in operating losses and a strategic transformation towards cannabinoid-based health sciences, including a rebranding to Endovia Health Sciences.

Splash Beverage Group, Inc. announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 24, 2026, signaling a strategic shift into the cannabinoid health sciences sector.

Splash Beverage Group, Inc. has filed amendments to its Articles of Incorporation to change its corporate name to Endovia Health Sciences, Inc., effective upon filing with the Nevada Secretary of State.

Splash Beverage Group announces a collaboration with Lupvindol Biosciences to advance CannEpil for veterinary use in companion-animal oncology and chronic pain management.

Splash Beverage Group enters a material definitive agreement with Lupvindol Biosciences Ltd. to develop a cannabinoid-based animal drug.

Splash Beverage Group announces an amendment to its exclusive global license for CannEpil, expanding its use to veterinary applications and adjusting royalty rates.

Splash Beverage Group has amended its exclusive global license for CannEpil to include veterinary applications, establishing a second regulated pharmaceutical development program.

Splash Beverage Group has amended settlement agreements with prior investors, extending payment deadlines and adjusting settlement amounts.

Splash Beverage Group, Inc. is implementing a one-for-four reverse stock split and has had its common stock trading halted by NYSE American due to trading below $0.10 per share.

Splash Beverage Group announced settlements with creditors reducing $3.3 million in liabilities to $550,000 and approved a 1-for-4 reverse stock split to aid NYSE American compliance.

Splash Beverage Group has entered into a letter agreement to settle its outstanding loan obligations totaling $2,834,689 for a reduced payment of $301,800.55.

Splash Beverage Group announced the sale of over 9.2 million shares of common stock, raising approximately $1.26 million in gross proceeds.

Splash Beverage Group announced NYSE American has accepted its plan to regain compliance with listing standards, granting a compliance period through January 29, 2027.

Splash Beverage Group secures exclusive worldwide rights to CannEpil, a cannabinoid formulation for drug-resistant epilepsy, through a new license agreement with Argent Biopharma.

Splash Beverage Group has acquired exclusive global licensing rights for CannEpil, a cannabinoid-based epilepsy therapy, from Argent BioPharma Limited, aiming to leverage existing European access and pursue U.S. regulatory advancement.

Splash Beverage Group issued 767,953 shares of common stock to C/M Capital Master Fund, LP for $117,036 in gross proceeds.

Splash Beverage Group announced a strategic CDN$300,000 investment in Avicanna Inc., a cannabinoid biopharmaceutical company, as part of its transformation into a health and wellness platform.

Splash Beverage Group appoints new COO, invests in Avicanna, and proposes a strategic RSU plan to drive transformation.

Splash Beverage Group provides an update on its NYSE American compliance plan and ongoing strategic transaction initiatives, aiming to strengthen its financial position and explore opportunities in the cannabinoid wellness sector.

Splash Beverage Group announces Brady Cobb as Interim CEO, signaling a strategic pivot towards wellness and cannabinoid markets while William Meissner resigns as President.